PT-141 (bremelanotide): a desire medicine that works in the brain, and how big the effect really is
Most people know the blood-flow pills for erectile problems. Far fewer know there is an approved medicine for low sexual desire in women that works in a completely different place: the brain. It is a peptide called bremelanotide, often known by its research name PT-141.
How many proteins have we read since Fred Sanger read the first one?
Every protein medicine you have ever heard of, from insulin to semaglutide, rests on one idea: a protein is a chain of building blocks in a fixed order, and the order can be read. Someone had to prove that first. That someone was Fred Sanger, and the protein was insulin.
Aspirin vs blood thinners after hip or knee replacement: what the PEPPER trial found
If you are about to have a hip or knee replaced, someone will talk to you about blood clots. For years the choice has been between a simple aspirin and a stronger anticoagulant, and earlier studies gave conflicting answers.
Stronger grip, lower odds of erectile dysfunction: what the Baylor review found
A stronger grip has been tied to lower odds of erectile dysfunction. It is the kind of line that spreads fast on social media, so I went to the peer-reviewed paper behind it.
A digital model of your child’s eye: testing glasses before they exist
Every parent who has taken a child for glasses knows the routine.
Sermorelin: the approved peptide that disappeared, and what the human studies found
Patients ask me about sermorelin more than almost any other peptide. Some have read that it is a gentler way to raise growth hormone. Others have heard that it was once FDA approved and wonder why it disappeared.
A shot every three months for severe triglycerides, and fewer cases of pancreatitis
There is one lab number I never ignore when it comes back very high: triglycerides. Most people think of them as a heart number. At severe levels they are also a pancreas number, because very high triglycerides can trigger acute pancreatitis, one of the most painful emergencies in medicine.
A digital twin for the placebo group? A proof-of-principle in premature babies
Every randomized trial asks a hard question of the families in it: will your child be in the group that gets the new treatment, or the group that does not? In neonatal medicine that question is heavier than anywhere else.